Amelia K Boehme1, Leslie A McClure2, Yu Zhang2, Jorge M Luna2, Oscar H Del Brutto2, Oscar R Benavente2, Mitchell S V Elkind2. 1. From the Department of Neurology, College of Physicians and Surgeons (A.K.B., J.M.L., M.S.V.E.) and Department of Epidemiology, Mailman School of Public Health (A.K.B., M.S.V.E.), Columbia University, New York; Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA (L.A.M.); Department of Biostatistics, School of Public Health, University of Alabama at Birmingham (Y.Z.); Department of Neurological Sciences, Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador (O.H.D.B.); and Department of Neurology, University of British Columbia, Vancouver, Canada (O.R.B.). akb2188@cumc.columbia.edu. 2. From the Department of Neurology, College of Physicians and Surgeons (A.K.B., J.M.L., M.S.V.E.) and Department of Epidemiology, Mailman School of Public Health (A.K.B., M.S.V.E.), Columbia University, New York; Department of Epidemiology and Biostatistics, Dornsife School of Public Health, Drexel University, Philadelphia, PA (L.A.M.); Department of Biostatistics, School of Public Health, University of Alabama at Birmingham (Y.Z.); Department of Neurological Sciences, Universidad de Especialidades Espíritu Santo, Guayaquil, Ecuador (O.H.D.B.); and Department of Neurology, University of British Columbia, Vancouver, Canada (O.R.B.).
Abstract
BACKGROUND AND PURPOSE: We hypothesized that concentrations of interleukin 6 (IL-6), serum amyloid A, tumor necrosis factor-α receptor 1, CD40 ligand, and monocyte chemoattractant protein 1 would predict recurrent ischemic stroke and major vascular events after recent lacunar stroke. METHODS: Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) was an international, multicenter, prospective ancillary biomarker study nested within the Secondary Prevention of Small Subcortical Strokes (SPS3) study, a Phase III trial in patients with recent lacunar stroke. Crude and Adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CI) for recurrence risks. RESULTS: Among 1244 patients with lacunar stroke (mean age, 63.3±10.8 years), there were 115 major vascular events (stroke, myocardial infarction, and vascular death). The risk of major vascular events increased with elevated concentrations of both tumor necrosis factor-α receptor 1 (adjusted HR per SD, 1.21; 95% CI, 1.05-1.41; P=0.01) and IL-6 (adjusted HR per SD, 1.10; 95% CI, 1.02-1.19; P=0.008). Compared with the bottom quartile (tumor necrosis factor-α receptor 1 <2.24 ng/L), those in the top quartile of tumor necrosis factor-α receptor 1 (>3.63 ng/L) were at twice the risk of major vascular events after adjusting for demographics (partially adjusted HR, 1.98; 95% CI, 1.11-3.52), though the effect attenuated after adjusting for other risk factors and statin use (adjusted HR, 1.68; 95% CI, 0.93-3.04). Serum amyloid A, CD40 ligand, and monocyte chemoattractant protein 1 were not associated with prognosis. CONCLUSIONS: Among recent lacunar stroke patients, IL-6 and TNF receptor concentrations predict risk of recurrent vascular events, and they are associated with the effect of antiplatelet therapies. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.
BACKGROUND AND PURPOSE: We hypothesized that concentrations of interleukin 6 (IL-6), serum amyloid A, tumor necrosis factor-α receptor 1, CD40 ligand, and monocyte chemoattractant protein 1 would predict recurrent ischemic stroke and major vascular events after recent lacunar stroke. METHODS: Levels of Inflammatory Markers in the Treatment of Stroke (LIMITS) was an international, multicenter, prospective ancillary biomarker study nested within the Secondary Prevention of Small Subcortical Strokes (SPS3) study, a Phase III trial in patients with recent lacunar stroke. Crude and Adjusted Cox proportional hazards models were used to calculate hazard ratios (HRs) and 95% confidence intervals (95% CI) for recurrence risks. RESULTS: Among 1244 patients with lacunar stroke (mean age, 63.3±10.8 years), there were 115 major vascular events (stroke, myocardial infarction, and vascular death). The risk of major vascular events increased with elevated concentrations of both tumor necrosis factor-α receptor 1 (adjusted HR per SD, 1.21; 95% CI, 1.05-1.41; P=0.01) and IL-6 (adjusted HR per SD, 1.10; 95% CI, 1.02-1.19; P=0.008). Compared with the bottom quartile (tumor necrosis factor-α receptor 1 <2.24 ng/L), those in the top quartile of tumor necrosis factor-α receptor 1 (>3.63 ng/L) were at twice the risk of major vascular events after adjusting for demographics (partially adjusted HR, 1.98; 95% CI, 1.11-3.52), though the effect attenuated after adjusting for other risk factors and statin use (adjusted HR, 1.68; 95% CI, 0.93-3.04). Serum amyloid A, CD40 ligand, and monocyte chemoattractant protein 1 were not associated with prognosis. CONCLUSIONS: Among recent lacunar strokepatients, IL-6 and TNF receptor concentrations predict risk of recurrent vascular events, and they are associated with the effect of antiplatelet therapies. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.
Authors: Oscar R Benavente; Carole L White; Lesly Pearce; Pablo Pergola; Ana Roldan; Marie-France Benavente; Christopher Coffey; Leslie A McClure; Jeff M Szychowski; Robin Conwit; Patricia A Heberling; George Howard; Carlos Bazan; Gabriela Vidal-Pergola; Robert Talbert; Robert G Hart Journal: Int J Stroke Date: 2011-01-26 Impact factor: 5.266
Authors: Oscar R Benavente; Robert G Hart; Leslie A McClure; Jeffrey M Szychowski; Christopher S Coffey; Lesly A Pearce Journal: N Engl J Med Date: 2012-08-30 Impact factor: 91.245
Authors: Kristian P Doyle; Lisa N Quach; Montse Solé; Robert C Axtell; Thuy-Vi V Nguyen; Gilberto J Soler-Llavina; Sandra Jurado; Jullet Han; Lawrence Steinman; Frank M Longo; Julie A Schneider; Robert C Malenka; Marion S Buckwalter Journal: J Neurosci Date: 2015-02-04 Impact factor: 6.167
Authors: Jorge M Luna; Yeseon Moon; Khin Liu; Steven Spitalnik; Myunghee Paik; Ralph Sacco; Mitchell S V Elkind Journal: Age Ageing Date: 2013-01-15 Impact factor: 10.668
Authors: Mitchell S V Elkind; Jorge M Luna; Leslie A McClure; Yu Zhang; Christopher S Coffey; Ana Roldan; Oscar H Del Brutto; Edwin Javier Pretell; L Creed Pettigrew; Brett C Meyer; Jorge Tapia; Carole White; Oscar R Benavente Journal: Stroke Date: 2014-02-12 Impact factor: 7.914
Authors: O R Benavente; C S Coffey; R Conwit; R G Hart; L A McClure; L A Pearce; P E Pergola; J M Szychowski Journal: Lancet Date: 2013-05-29 Impact factor: 79.321
Authors: L M Biasucci; A Vitelli; G Liuzzo; S Altamura; G Caligiuri; C Monaco; A G Rebuzzi; G Ciliberto; A Maseri Journal: Circulation Date: 1996-09-01 Impact factor: 29.690
Authors: Jorge M Luna; Yeseon P Moon; Khin M Liu; Steven Spitalnik; Myunghee C Paik; Keun Cheung; Ralph L Sacco; Mitchell S V Elkind Journal: Stroke Date: 2014-03-13 Impact factor: 7.914
Authors: Mandip S Dhamoon; Ying-Kuen Cheung; Yeseon P Moon; Clinton B Wright; Joshua Z Willey; Ralph L Sacco; Mitchell S V Elkind Journal: Am J Epidemiol Date: 2017-07-01 Impact factor: 4.897
Authors: Peter Kelly; Christian Weimar; Robin Lemmens; Sean Murphy; Francisco Purroy; Anita Arsovska; Natan M Bornstein; Anna Czlonkowska; Urs Fischer; Ana Catarina Fonseca; John Forbes; Michael D Hill; Dalius Jatuzis; Janika Kõrv; Christina Kruuse; Robert Mikulik; Paul J Nederkoorn; Martin O'Donnell; Peter Sandercock; David Tanne; Georgios Tsivgoulis; Cathal Walsh; David Williams; Marialuisa Zedde; Christopher I Price Journal: Eur Stroke J Date: 2021-06-18
Authors: J J McCabe; E O'Reilly; S Coveney; R Collins; L Healy; J McManus; R Mulcahy; B Moynihan; T Cassidy; F Hsu; B Worrall; S Murphy; M O'Donnell; P J Kelly Journal: Eur Stroke J Date: 2021-01-05